- Entry
- $2.57
- Final
- $1.65 -35.8%
- Target
- —
- Score
- -1.00
Regentis Biomaterials is a regenerative medicine company that develops biodegradable hydrogel implants to repair and regenerate damaged orthopedic tissue, specifically focused on focal knee cartilage injuries. Their lead product, GelrinC, is a cell-free, "off-the-shelf" implant made from a proprietary matrix of polyethylene glycol diacrylate and denatured fibrinoge Possible catalysts: annual general shareholder meeting at 8:00AM EST 2. Pivotal U.S. Phase III Trial Progress Regentis is targeting a massive U.S. addressable population of over 470,000 knee cartilage repair cases annually. **The …
— ORIGINAL POST ·
RGNT possible short squeeze potential 🍋
· r/smallstreetbets
· Jul 9, 2026